Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PERRIGO Co plcPRGO · Entity 4516 | Director | May 14, 2025 | May 16, 2025 |
| PRECIGEN, INC.PGEN · Entity 4356 | Director | August 26, 2026 | August 28, 2026 |
| Praxis Precision Medicines, Inc.PRAX · Entity 3538 | Director | June 10, 2026 | June 12, 2026 |
| SIGA TECHNOLOGIES INCSIGA · Entity 6205 | Director | May 21, 2020 | May 22, 2020 |
| vTv Therapeutics Inc.VTVT · Entity 6614 | Director | June 11, 2020 | June 15, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PERRIGO Co plc
Report date May 14, 2025 · Filed May 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 10,559 |
Ending reported balance
After 2025-05-14 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-05-14 · Exercise / conversion · Acquired 9,904 · Balance 15,313 Row 2 · 2025-05-14 · Tax withholding · Disposed 4,754 · Balance 10,559 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 7,305 |
Reported balance
After 2025-05-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-05-14 · Grant · Acquired 7,305 · Balance 7,305 F1: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F2: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 14 May 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-05-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-05-14 · Exercise / conversion · Disposed 9,904 · Balance 0 F1: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F3: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 14 May 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share.
F2: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 14 May 2026.
F3: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 14 May 2025.
PRECIGEN, INC.
Report date August 26, 2026 · Filed August 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,100 |
Reported balance
After 2026-08-26 transaction · row 1
1 source rowRow 1 · 2026-08-26 · Sale · Disposed 185,000 · Balance 17,100 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.38 to $7.59, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.38 to $7.59, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
Praxis Precision Medicines, Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,537 |
Reported balance
After 2026-06-10 transaction · row 1
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 1,371 · Balance 2,537 F1: Mr. Kindler was awarded 1,371 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in a single annual installment on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $240.66 · Expires 2036-06-10 | Direct | 648 |
Reported balance
After 2026-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-10 · Grant · Acquired 648 · Balance 648 F2: The shares subject to this option shall vest in twelve (12) equal monthly installments occurring on the 10th day of each month, with the first such installment occurring on July 10, 2026 and the final such installment occurring on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Kindler was awarded 1,371 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in a single annual installment on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
F2: The shares subject to this option shall vest in twelve (12) equal monthly installments occurring on the 10th day of each month, with the first such installment occurring on July 10, 2026 and the final such installment occurring on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders.
SIGA TECHNOLOGIES INC
Report date May 21, 2020 · Filed May 22, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, Par Value $.0001 Per ShareSEC Table I · non-derivative | Direct | 127,339 |
Reported balance
After 2020-05-21 transaction · row 1
1 source rowRow 1 · 2020-05-21 · Exercise / conversion · Acquired 15,000 · Balance 127,339 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-05-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-05-21 · Exercise / conversion · Disposed 15,000 · Balance 0 F1: Each restricted stock unit ("RSU") converts into one share of common stock of SIGA Technologies, Inc. on a one for one basis. F2: The RSUs were granted on May 21, 2019, and vested on the first anniversary of such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") converts into one share of common stock of SIGA Technologies, Inc. on a one for one basis.
F2: The RSUs were granted on May 21, 2019, and vested on the first anniversary of such date.
vTv Therapeutics Inc.
Report date June 11, 2020 · Filed June 15, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.65 · Expires 2030-06-11 | Direct | 78,121 |
Reported balance
After 2020-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-11 · Grant · Acquired 15,000 · Balance 78,121 F1: The option vests in monthly equal installments over the three year period beginning on June 11, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in monthly equal installments over the three year period beginning on June 11, 2020.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
PFIZER INC
Report date December 15, 2010 · Filed December 17, 2010
Section 16 reporting ended · disclosed 2010-12-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock Units SSPSEC Table II · derivative / convertible security | Direct | 62,194 |
Reported balance
After 2010-12-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2010-12-15 · Grant · Acquired 261 · Balance 62,194 F1: Each unit represents one phantom share of common stock. F2: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. |
Filing footnotes · ownership attribution and instrument terms
F1: Each unit represents one phantom share of common stock.
F2: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.
PPD, Inc.
Report date December 08, 2021 · Filed December 08, 2021
Section 16 reporting ended · disclosed 2021-12-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-12-08 transaction · row 1
1 source rowRow 1 · 2021-12-08 · Disposition to issuer · Disposed 99,487 · Balance 0 F1: On December 8, 2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F2: Includes 2,164 shares of common stock subject to a restricted stock unit grant (the "RSUs") which provided for vesting on the earlier of the one-year anniversary of the grant date and the date of the next regularly scheduled annual meeting of stockholders of the Issuer. At the effective time of the Merger, the RSUs were canceled and converted into the right to receive an amount of cash equal to the Merger Consideration (as defined below) multiplied by the number of restricted stock units being so canceled and converted. F3: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $47.50 in cash (the "Merger Consideration"). |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 0 |
Reported balance
After 2021-12-08 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2021-12-08 · Disposition to issuer · Disposed 18,500 · Balance 0 F1: On December 8, 2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F2: Includes 2,164 shares of common stock subject to a restricted stock unit grant (the "RSUs") which provided for vesting on the earlier of the one-year anniversary of the grant date and the date of the next regularly scheduled annual meeting of stockholders of the Issuer. At the effective time of the Merger, the RSUs were canceled and converted into the right to receive an amount of cash equal to the Merger Consideration (as defined below) multiplied by the number of restricted stock units being so canceled and converted. F3: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $47.50 in cash (the "Merger Consideration"). |
Filing footnotes · ownership attribution and instrument terms
F1: On December 8, 2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger").
F2: Includes 2,164 shares of common stock subject to a restricted stock unit grant (the "RSUs") which provided for vesting on the earlier of the one-year anniversary of the grant date and the date of the next regularly scheduled annual meeting of stockholders of the Issuer. At the effective time of the Merger, the RSUs were canceled and converted into the right to receive an amount of cash equal to the Merger Consideration (as defined below) multiplied by the number of restricted stock units being so canceled and converted.
F3: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $47.50 in cash (the "Merger Consideration").
Terns Pharmaceuticals, Inc.
Report date May 05, 2026 · Filed May 05, 2026
Section 16 reporting ended · disclosed 2026-05-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.82 | Direct | 0 |
Reported balance
After 2026-05-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-05 · Disposition to issuer · Disposed 32,000 · Balance 0 F1: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price. F2: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.10 | Direct | 0 |
Reported balance
After 2026-05-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-05 · Disposition to issuer · Disposed 45,000 · Balance 0 F1: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price. F2: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.46 | Direct | 0 |
Reported balance
After 2026-05-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-05 · Disposition to issuer · Disposed 10,657 · Balance 0 F1: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price. F2: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.85 | Direct | 0 |
Reported balance
After 2026-05-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-05 · Disposition to issuer · Disposed 4,676 · Balance 0 F1: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price. F2: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.99 | Direct | 0 |
Reported balance
After 2026-05-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-05 · Disposition to issuer · Disposed 32,000 · Balance 0 F1: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price. F2: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.24 | Direct | 0 |
Reported balance
After 2026-05-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-05-05 · Disposition to issuer · Disposed 28,475 · Balance 0 F1: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price. F2: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.72 | Direct | 0 |
Reported balance
After 2026-05-05 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-05-05 · Disposition to issuer · Disposed 22,000 · Balance 0 F1: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price. F2: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.05 | Direct | 0 |
Reported balance
After 2026-05-05 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-05-05 · Disposition to issuer · Disposed 32,000 · Balance 0 F1: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price. F2: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.60 | Direct | 0 |
Reported balance
After 2026-05-05 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-05-05 · Disposition to issuer · Disposed 1,697 · Balance 0 F1: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price. F2: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.
F2: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 29, 2006 Filed Oct 3, 2006 22:18 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 89 | $28.36 | $2,524.04 |
DisclosureSEC source: 0000078003-06-000255 · kin1332.xml · derivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,998 Underlying: Common Stock · 89 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and, subject to certain conditions, may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and, subject to certain conditions, may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| September 15, 2006 Filed Sep 18, 2006 18:40 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 89 | $28.04 | $2,495.56 |
DisclosureSEC source: 0000078003-06-000241 · kin1318.xml · derivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,909 Underlying: Common Stock · 89 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and, subject to certain conditions, may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and, subject to certain conditions, may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| September 05, 2006 Filed Sep 5, 2006 17:32 UTC | PFIZER INC PFE · Entity 2863 | GiftCommon Stock | 1,850 | $0.00 | $0.00 |
DisclosureSEC source: 0000078003-06-000230 · kin1314.xml · nonDerivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,699 Read SEC document |
| August 31, 2006 Filed Sep 5, 2006 17:32 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 87 | $27.56 | $2,397.72 |
DisclosureSEC source: 0000078003-06-000230 · kin1314.xml · derivative · entry 3 KINDLER JEFFREY B · CIK 0001174454 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,820 Underlying: Common Stock · 87 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and, subject to certain conditions, may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and, subject to certain conditions, may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| August 15, 2006 Filed Aug 17, 2006 15:15 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 185 | $26.40 | $4,884.00 |
DisclosureSEC source: 0000078003-06-000208 · kin1272.xml · derivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,733 Underlying: Common Stock · 185 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and, subject to certain conditions, may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and, subject to certain conditions, may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| July 31, 2006 Filed Aug 1, 2006 20:59 UTC | PFIZER INC PFE · Entity 2863 | GrantEmployee Stock Option (right to buy) · Derivative | 500,000 | $0.00 Strike: $26.29 | $0.00 |
DisclosureSEC source: 0000078003-06-000181 · kin1251.xml · derivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2016-07-30 F1 · derivative.exercise_date: The options will become exercisable upon the fifth anniversary of the date of grant, provided, however, that the options may not be exercised unless and until the average closing price of Pfizer common stock for 20 consecutive trading days exceeds 150% of the exercise price. Read SEC document |
| July 31, 2006 Filed Aug 2, 2006 14:11 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 66 | $25.99 | $1,715.34 |
DisclosureSEC source: 0000078003-06-000185 · kin1255.xml · derivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,548 Underlying: Common Stock · 66 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and, subject to certain conditions, may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and, subject to certain conditions, may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| July 14, 2006 Filed Jul 17, 2006 18:58 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 79 | $22.41 | $1,770.39 |
DisclosureSEC source: 0000078003-06-000176 · kin1246.xml · derivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,482 Underlying: Common Stock · 79 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and, subject to certain conditions, may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and, subject to certain conditions, may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| June 30, 2006 Filed Jul 5, 2006 16:45 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 76 | $23.47 | $1,783.72 |
DisclosureSEC source: 0000078003-06-000166 · kin1235.xml · derivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,403 Underlying: Common Stock · 76 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and, subject to certain conditions, may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and, subject to certain conditions, may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| June 15, 2006 Filed Jun 19, 2006 15:45 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 73 | $23.53 | $1,717.69 |
DisclosureSEC source: 0000078003-06-000142 · kin1227.xml · derivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,327 Underlying: Common Stock · 73 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and, subject to certain conditions, may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and, subject to certain conditions, may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| May 31, 2006 Filed Jun 2, 2006 15:49 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 80 | $23.66 | $1,892.80 |
DisclosureSEC source: 0000078003-06-000131 · kin1219.xml · derivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,254 Underlying: Common Stock · 80 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and, subject to certain conditions, may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and, subject to certain conditions, may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| May 15, 2006 Filed May 17, 2006 20:33 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 158 | $24.89 | $3,932.62 |
DisclosureSEC source: 0000078003-06-000120 · kin1210.xml · derivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,174 Underlying: Common Stock · 158 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and, subject to certain conditions, may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and, subject to certain conditions, may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| April 28, 2006 Filed May 2, 2006 21:02 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 70 | $25.33 | $1,773.10 |
DisclosureSEC source: 0000078003-06-000105 · kin1201.xml · derivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,016 Underlying: Common Stock · 70 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. Read SEC document |
| April 17, 2006 Filed Apr 19, 2006 14:40 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 72 | $24.44 | $1,759.68 |
DisclosureSEC source: 0000078003-06-000078 · kin1178.xml · derivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,946 Underlying: Common Stock · 72 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. Read SEC document |
| April 07, 2006 Filed Apr 10, 2006 16:49 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 37 | $26.05 | $963.85 |
DisclosureSEC source: 0000078003-06-000069 · kin1172.xml · nonDerivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,703 Read SEC document |
| March 31, 2006 Filed Apr 4, 2006 18:29 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 67 | $24.92 | $1,669.64 |
DisclosureSEC source: 0000078003-06-000061 · kin1163.xml · derivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,874 Underlying: Common Stock · 67 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. Read SEC document |
| March 15, 2006 Filed Mar 17, 2006 16:56 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 1,678 | $25.95 | $43,544.10 |
DisclosureSEC source: 0000078003-06-000051 · kin1151.xml · derivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,807 Underlying: Common Stock · 1,678 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. Read SEC document |
| February 27, 2006 Filed Mar 1, 2006 16:37 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 3,055 | $26.55 | $81,110.25 |
DisclosureSEC source: 0000078003-06-000042 · kin1142.xml · nonDerivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,657 Read SEC document |
| February 23, 2006 Filed Feb 24, 2006 22:35 UTC | PFIZER INC PFE · Entity 2863 | GrantEmployee Stock Option (right to buy) · Derivative | 400,000 | $0.00 Strike: $26.20 | $0.00 |
DisclosureSEC source: 0000078003-06-000033 · kin1133.xml · derivative · entry 4 KINDLER JEFFREY B · CIK 0001174454 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2016-02-22 Read SEC document |
| February 23, 2006 Filed Feb 24, 2006 22:35 UTC | PFIZER INC PFE · Entity 2863 | GrantCommon Stock | 39,840 | $0.00 | $0.00 |
DisclosureSEC source: 0000078003-06-000033 · kin1133.xml · nonDerivative · entry 2 KINDLER JEFFREY B · CIK 0001174454 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,712 F2 · shares: The reported transaction constitutes the earn-out of Performance-Contingent Shares. Read SEC document |
| February 23, 2006 Filed Feb 24, 2006 22:35 UTC | PFIZER INC PFE · Entity 2863 | GrantCommon Stock | 27,690 | $0.00 | $0.00 |
DisclosureSEC source: 0000078003-06-000033 · kin1133.xml · nonDerivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,872 F1 · shares: The reported transaction constitutes the grant of Restricted Stock Units. Read SEC document |
| December 30, 2005 Filed Jan 4, 2006 18:41 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 70 | $23.32 | $1,632.40 |
DisclosureSEC source: 0000078003-06-000008 · kin1101.xml · derivative · entry 3 KINDLER JEFFREY B · CIK 0001174454 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,066 Underlying: Common Stock · 70 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. Read SEC document |
| December 30, 2005 Filed Jan 4, 2006 18:41 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 1,502 | $23.34 | $35,056.68 |
DisclosureSEC source: 0000078003-06-000008 · kin1101.xml · nonDerivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,180 Read SEC document |
| December 15, 2005 Filed Dec 19, 2005 17:37 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 73 | $22.79 | $1,663.67 |
DisclosureSEC source: 0000078003-05-000306 · kin1089.xml · derivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,996 Underlying: Common Stock · 73 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. Read SEC document |
| November 30, 2005 Filed Dec 1, 2005 20:01 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 83 | $21.20 Strike: $0.00 | $1,759.60 |
DisclosureSEC source: 0000078003-05-000292 · kin1079.xml · derivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,923 Underlying: Common Stock · 83 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. Read SEC document |
| November 15, 2005 Filed Nov 17, 2005 17:54 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 135 | $21.89 Strike: $0.00 | $2,955.15 |
DisclosureSEC source: 0000078003-05-000283 · kin1070.xml · derivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,840 Underlying: Common Stock · 135 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. Read SEC document |
| November 01, 2005 Filed Nov 2, 2005 21:53 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 80 | $21.55 Strike: $0.00 | $1,724.00 |
DisclosureSEC source: 0000078003-05-000266 · kin1059.xml · derivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,705 Underlying: Common Stock · 80 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. Read SEC document |
| October 14, 2005 Filed Oct 18, 2005 19:05 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 68 | $24.32 Strike: $0.00 | $1,653.76 |
DisclosureSEC source: 0000078003-05-000256 · kin1049.xml · derivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,625 Underlying: Common Stock · 68 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. Read SEC document |
| September 30, 2005 Filed Oct 3, 2005 21:15 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 68 | $24.97 Strike: $0.00 | $1,697.96 |
DisclosureSEC source: 0000078003-05-000244 · kin1037.xml · derivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,557 Underlying: Common Stock · 68 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. Read SEC document |
| September 15, 2005 Filed Sep 16, 2005 15:26 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 66 | $25.70 Strike: $0.00 | $1,696.20 |
DisclosureSEC source: 0000078003-05-000236 · kin1029.xml · derivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,489 Underlying: Common Stock · 66 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. Read SEC document |
| August 31, 2005 Filed Sep 2, 2005 15:52 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 68 | $25.47 Strike: $0.00 | $1,731.96 |
DisclosureSEC source: 0000078003-05-000227 · kin1018.xml · derivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,423 Underlying: Common Stock · 68 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. Read SEC document |
| August 15, 2005 Filed Aug 16, 2005 20:19 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 110 | $26.20 Strike: $0.00 | $2,882.00 |
DisclosureSEC source: 0000078003-05-000218 · kin1009.xml · derivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,355 Underlying: Common Stock · 110 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. Read SEC document |
| July 29, 2005 Filed Aug 1, 2005 19:49 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 64 | $26.50 Strike: $0.00 | $1,696.00 |
DisclosureSEC source: 0000078003-05-000205 · kin1001.xml · derivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,245 Underlying: Common Stock · 64 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. Read SEC document |
| July 15, 2005 Filed Jul 19, 2005 13:57 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 62 | $27.57 Strike: $0.00 | $1,709.34 |
DisclosureSEC source: 0000078003-05-000193 · kin993.xml · derivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,181 Underlying: Common Stock · 62 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. Read SEC document |
| June 30, 2005 Filed Jul 1, 2005 18:55 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 61 | $27.58 Strike: $0.00 | $1,682.38 |
DisclosureSEC source: 0000078003-05-000183 · kin980.xml · derivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,119 Underlying: Common Stock · 61 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. Read SEC document |
| June 15, 2005 Filed Jun 17, 2005 12:16 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 59 | $28.43 Strike: $0.00 | $1,677.37 |
DisclosureSEC source: 0000078003-05-000155 · kin976.xml · derivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,058 Underlying: Common Stock · 59 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. Read SEC document |
| May 31, 2005 Filed Jun 1, 2005 17:33 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 61 | $27.90 Strike: $0.00 | $1,701.90 |
DisclosureSEC source: 0000078003-05-000143 · kin964.xml · derivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,999 Underlying: Common Stock · 61 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. Read SEC document |
| May 13, 2005 Filed May 16, 2005 17:38 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 100 | $27.86 Strike: $0.00 | $2,786.00 |
DisclosureSEC source: 0000078003-05-000134 · kin955.xml · derivative · entry 4 KINDLER JEFFREY B · CIK 0001174454 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,938 Underlying: Common Stock · 100 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. Read SEC document |
| May 13, 2005 Filed May 16, 2005 17:38 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 12,300 | $27.66 | $340,218.00 |
DisclosureSEC source: 0000078003-05-000134 · kin955.xml · nonDerivative · entry 2 KINDLER JEFFREY B · CIK 0001174454 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,084 Read SEC document |
| May 13, 2005 Filed May 16, 2005 17:38 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 1,700 | $27.67 | $47,039.00 |
DisclosureSEC source: 0000078003-05-000134 · kin955.xml · nonDerivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,384 Read SEC document |
| May 10, 2005 Filed May 11, 2005 14:46 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 5,900 | $27.68 | $163,312.00 |
DisclosureSEC source: 0000078003-05-000130 · kin951.xml · nonDerivative · entry 2 KINDLER JEFFREY B · CIK 0001174454 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,084 Read SEC document |
| May 10, 2005 Filed May 11, 2005 14:46 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 100 | $27.69 | $2,769.00 |
DisclosureSEC source: 0000078003-05-000130 · kin951.xml · nonDerivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,984 Read SEC document |
| April 29, 2005 Filed May 3, 2005 18:56 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 63 | $27.17 Strike: $0.00 | $1,711.71 |
DisclosureSEC source: 0000078003-05-000117 · kin942.xml · derivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,838 Underlying: Common Stock · 63 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. Read SEC document |
| April 15, 2005 Filed Apr 19, 2005 15:03 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 60 | $27.71 Strike: $0.00 | $1,662.60 |
DisclosureSEC source: 0000078003-05-000094 · kin920.xml · derivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,775 Underlying: Common Stock · 60 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. Read SEC document |
| March 31, 2005 Filed Apr 1, 2005 16:48 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 64 | $26.27 Strike: $0.00 | $1,681.28 |
DisclosureSEC source: 0000078003-05-000081 · kin906.xml · derivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,715 Underlying: Common Stock · 64 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. Read SEC document |
| March 15, 2005 Filed Mar 16, 2005 20:06 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 64 | $26.29 Strike: $0.00 | $1,682.56 |
DisclosureSEC source: 0000078003-05-000074 · kin897.xml · derivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,651 Underlying: Common Stock · 64 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. Read SEC document |
| March 11, 2005 Filed Mar 15, 2005 15:54 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 1,381 | $26.36 Strike: $0.00 | $36,403.16 |
DisclosureSEC source: 0000078003-05-000065 · kin888.xml · derivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,587 Underlying: Common Stock · 1,381 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. Read SEC document |
| February 24, 2005 Filed Feb 28, 2005 20:09 UTC | PFIZER INC PFE · Entity 2863 | GrantEmployee Stock Option (right to buy) · Derivative | 261,000 | $0.00 Strike: $26.20 | $0.00 |
DisclosureSEC source: 0000078003-05-000047 · kin876.xml · derivative · entry 4 KINDLER JEFFREY B · CIK 0001174454 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,000 Underlying: Common Stock · 261,000 shares Expires 2015-02-26 F2 · derivative.exercise_date: This option becomes exercisable in 3 equal annual installments beginning on February 24, 2008. Read SEC document |
| February 24, 2005 Filed Feb 28, 2005 20:09 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 12,989 | $26.20 | $340,311.80 |
DisclosureSEC source: 0000078003-05-000047 · kin876.xml · nonDerivative · entry 2 KINDLER JEFFREY B · CIK 0001174454 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,036 Read SEC document |
| February 24, 2005 Filed Feb 28, 2005 20:09 UTC | PFIZER INC PFE · Entity 2863 | GrantCommon Stock | 49,980 | $0.00 | $0.00 |
DisclosureSEC source: 0000078003-05-000047 · kin876.xml · nonDerivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,025 F1 · shares: The reported transaction constitutes the earn-out of Performance-Contingent Shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.